Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity

Toxicology in Vitro

Volumn 20, Issue 5, 2006, Pages 535-546

  Höschele, Doris ^a  

^a Federal Institute for Drugs and Medical Devices   (Germany)

Author keywords

Cell culture; HAART; HIV; In vitro; Mitochondria; NRTI

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDYLTRANSFERASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

BRAIN DISEASE; CARDIOMYOPATHY; CELL CULTURE; DRUG EXPOSURE; DRUG SAFETY; ERADICATION THERAPY; FATTY LIVER; HEART MUSCLE CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LYMPHOBLASTOID CELL LINE; MITOCHONDRIAL TOXICITY; MORBIDITY; NERVE CELL; NEUROPATHY; NONHUMAN; PANCREATITIS; PRENATAL EXPOSURE; REVIEW; SCREENING; T LYMPHOCYTE; TISSUE SPECIFICITY; TREATMENT OUTCOME; VALIDATION PROCESS; VIRUS REPLICATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELLS, CULTURED; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MUSCLE CELLS; NEURONS; ORGAN SPECIFICITY; PANCREAS; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33744785655     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2005.11.007     Document Type: Review

References (48)

1. Anderson P.L., Kakuda T.N., and Lichtenstein K.A. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clinical Infectious Diseases 38 (2004) 743-753
2. Benbrik E., Chariot P., Bonavaud S., Ammi-Saïd M., Frisdal E., Rey C., Gherardi R., and Barlovatz-Meimonn G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. Journal of Neurological Sciences 149 (1997) 19-25
3. Birkus G., Hitchcock M.J.M., and Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 46 (2002) 716-723
4. Blanche S., Tardieu M., Rustin P., Slama A., Barret B., Firton G., Cirara-Vigneron N., Lacroix C., Rouzioux C., Mandelbrot L., Desguerre I., Rötig A., Mayaux M.-J., and Delfraissy J.-F. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. The Lancet 354 (1999) 1084-1089
5. Brinkman K., ter Hofstede H.J.M., Burger D.M., Smeitink J.A.M., and Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 12 (1998) 1735-1744
6. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy. The Lancet 356 (2000) 1423-1429
7. Casula M., Bosboom-Dobbelaer I., Smolders K., Otto S., Bakker M., deBaar M.P., Reiss P., and deRonde A. Infection with HIV-1 induces decrease in mtDNA. Journal of Infectious Diseases 191 (2005) 1468-1471
8. Cazzalini O., Lazze M.C., Iamele L., Stivala L.A., Bianchi L., Vaghi P., Cornaglia A., Calligaro A., Curti D., Alessandrini A., Prosperi E., and Tannini V. Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochemical Pharmacology 62 (2001) 893-902
9. Chen C.H., Vazquez-Padua M., and Cheng Y.C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Molecular Pharmacology 39 (1991) 625-628
10. Cherrington J.M., Allen S.J.W., Bischofberger N., and Chen M.S. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human polymerase α, β and γ. Antiviral Chemistry and Chemotherapy 6 (1995) 217-221
11. Cihlar T., and Chen M.S. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases α, β and γ. Antiviral Chemistry and Chemotherapy 8 (1997) 187-195
12. Cossarizza A., and Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18 (2004) 137-151
13. Cote H.C.F., Brumme Z.L., Craib K.J.B., Alexander C.S., Wynhoven B., Ting L., Wong H., Harris M., Harrigan R., O'Shaughnessy M.V., and Montaner L.S.G. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. The New England Journal of Medicine 346 (2002) 811-820
14. Cui L., Locatelli L., Xie M.Y., and Sommadossi J.P. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. The Journal of Pharmacology and Experimental Therapeutics 280 (1997) 1228-1234
15. Dagan T., Sable C., Bray J., and Gerschenson M. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence?. Mitochondrion 1 (2002) 397-412
16. De Mendoza C., Sanchez-Conde M., Ribera E., and Domingo P. Could mitochondrial DNA quantification be a surrogate marker for drug mitochondrial toxicity?. AIDS Reviews 6 (2004) 169-180
17. De Mendoza C., De Ronde A., Smolders K., Blanco F., Garcia-Banayas T., De Baar M., Fernandez-Casas P., Gonzalez-Lahoz J., and Soriano V. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Research and Human Retroviruses 20 (2004) 271-273
18. DiMauro S., and Schon E.A. Mitochondrial respiratory-chain diseases. The New England Journal of Medicine 348 (2003) 2656-2668
19. Haas R.H. A comparison of genetic mitochondrial disease and nucleoside analogue toxicity. Annals New York Academy of Science 918 (2000) 247-261
20. Hart G.J., Orr D.C., Pen C.R., Figueiredo H.T., Gray N.M., Boehme R.E., and Cameron J.M. Effects of (-)-2′-Deoxy-3′-thiacytidine (3TC)5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrobial Agents and Chemotherapy 36 (1992) 1688-1694
21. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., and Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. The Journal of Biological Chemistry 276 (2001) 40847-40857
22. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics 22 (2000) 685-708
23. Lake-Bakaar G., Mazzoccoli V., Dickman K., and Lyubsky S. Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells. Digestive Diseases and Sciences 46 (2001) 1853-1863
24. Leary S.C., Battersby B.J., Hansford R.G., and Moyes C.D. Interactions between bioenergetics and mitochondrial biogenesis. Biochimica et Biophysica Acta 1365 (1998) 522-530
25. Lee H., Hanes J., and Johnson K.A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42 (2003) 14711-14719
26. Lewis W., Copeland W.C., and Day B.J. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Laboratory Investigation 81 (2001) 777-790
27. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nature Reviews 2 (2003) 812-822
28. Lewis W., and Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nature Medicine 1 (1995) 417-422
29. Lim S.E., and Copeland W.C. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase γ. Journal of Biological Chemistry 276 (2001) 23616-23623
30. Lund K.C., and Fallace K.B. Direct, DNA pol-γ -independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovascular Toxicology 4 (2004) 217-218
31. Martin J.L., Brown C.E., Matthews-Davids N., and Reardon J.E. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents and Chemotherapy 38 (1994) 2743-2749
32. Masini A., Scotti C., Calligaro A., Cazzalini O., Stivala L.A., Bianchi L., Giovannini F., Ceccarelli D., Muscatello U., Tomasi A., and Vannini V. Zidovudine-induced experimental myopathy; dual mechanism of mitochondrial damage. Journal of the Neurological Sciences 166 (1999) 131-140
33. Medina D.L., Tsai C.-H., Hsiung G.D., and Cheng Y.-C. Comparison of mitochondrial morphology, mitochondrial DNA content and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleotides. Antimicrobial Agents and Chemotherapy 38 (1994) 1824-1828
34. Moroni M., and Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS 17 Suppl. 1 (2003) S51-S64
35. Moyle G. Clinical manifestation and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clinical Therapeutics 22 (2000) 911-936
36. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues. Is mitochondrial toxicity the only mechanism?. Drug Safety 23 (2000) 467-481
37. Moyle G. Mitochondrial toxicity: myths and facts. Journal of HIV Therapy 9 (2004) 45-47
38. Pan-Zhou X.R., Cui L., Zhou X.J., Sommadossi J.P., and Darley-Usmar V.M. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrobial Agents and Chemotherpapy 44 (2000) 496-503
39. Pinti M., Troiano L., Nasi M., Ferraresi R., Dobrucki J., and Cossarizza A. Hepatoma HepG2 cells as a model for in vitro studies on mitochondrial toxicity of antiviral drugs: which correlation with the patient. Journal of Biological Regulators and Homeostatic Agents 17 (2003) 166-171
40. Poirier M., Divi R.L., Al-Harthi L., Olivero O.A., Nguyen V., Walzer B., Landay A.L., Walzer V.E., Charrurat M., and Blattner W.A. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. Journal of Aquired Immune Deficiency Sydromes 33 (2003) 175-183
41. Pomerantz R.J., and Horn D.L. Twenty years of therapy for HIV-1 infection. Nature Medicine 9 (2003) 867-873
42. Rylova S.N., Albertioni F., Flygh G., and Eriksson S. Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochemical Pharmacology 69 (2005) 951-960
43. Squires K.E. An introduction to nucleoside and nucleotide analogues. Antiviral Therapy 6 (2001) 1-14
44. Valenti D., Barile M., and Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. International Journal of Molecular Medicine 6 (2000) 93-96
45. Van den Bogert C., Spelbrink J.N., and Dekker H.L. Relationship between culture conditions and the dependency on mitochondrial function of mammalian cell proliferation. Journal of Cellular Physiology 152 (1992) 632-638
46. Walker U.A., Setzer B., and Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16 (2002) 2165-2173
47. Walker U.A. Update on mitochondrial toxicity: where are we now?. Journal of HIV Therapy 8 (2003) 32-35
48. Weber K., Ridderskamp D., Alfert M., Hoyer S., and Wiesner R.J. Cultivation in glucose-deprived medium stimulates mitochondrial biogenesis and oxidative metabolism in HepG2 cells. Biological Chemistry 383 (2002) 283-290